Delivering on commitments: Werfen's strategic achievements and financial success

2024 has been a strong year, with sales reaching €2.2 billion and delivering outstanding business and financial performance. Our EBITDA margins have improved by 50 basis points, showcasing our commitment to excellence.

Our financial discipline and conservative approach have enabled us to fulfill our deleveraging commitment to the financial and investor communities. We successfully reduced our Net Debt-to-EBITDA ratio below 3x in less than 24 months following the Immucor acquisition—achieving this milestone three months ahead of schedule.

At the same time, we have continued to execute our strategic priorities, enhancing our focus on specialized diagnostics. The integration of Immucor continues to progress as planned, we divested our Medical Device distribution business, and we acquired Omixon to further strengthen our Transplant business line.

Our strong performance this year was driven by broad growth across our business lines and regions, with North America surpassing Europe in revenue contribution for the first time. The successful launch of new products in Acute Care (GEM Premier 7000) and Hemostasis (ACL TOP Family 70 Series) further reinforced our commitment to innovation and strengthened our leadership in specialized diagnostics.

On the financing front, we strengthened our financial position by reducing gross debt by €256 million. In April, we successfully issued our third bond (€500 million), further cementing our reputation as a well-established issuer in the capital markets and expanding our investor base. The issue helped extend our debt maturity profile, ensuring financial flexibility for the years ahead.

Despite a year marked by geopolitical tensions and global uncertainty, Werfen has once again demonstrated the resilience of its financial fundamentals, positioning us for continued success in the years ahead.